Baseline characteristics of patients with baseline ≥3% BSA and ≥10% BSA
| SPIRIT Trial Integrated Database | ||
| ≥3% BSA (n=402)* | ≥10% BSA (n=224)† | |
| Age, years | 49.8 (11.6) | 49.1 (11.7) |
| Male | 206 (51.2%) | 131 (58.5%) |
| Weight, kg | 87.8 (21.4) | 88.4 (21.8) |
| BMI, kg/m2 | 30.5 (7.4) | 30.2 (7.4) |
| Race | ||
| White | 369 (92.0%) | 199 (89.2%) |
| Asian | 22 (5.5%) | 18 (8.1%) |
| Other | 10 (2.4%) | 6 (2.7%) |
| Time since psoriatic arthritis diagnosis, years | 8.6 (7.9) | 8.7 (7.6) |
| Time since psoriasis diagnosis, years | 16.9 (12.6) | 17.5 (12.4) |
| cDMARD current use | 226 (56.2%) | 122 (54.5%) |
| Methotrexate current use | 188 (46.8%) | 104 (46.4%) |
| Prior TNFi experience | 203 (50.5%) | 106 (47.3%) |
| Baseline disease scores | ||
| Tender joint count, 68 joints | 22.1 (15.0) | 22.3 (14.9) |
| Swollen joint count, 66 joints | 11.9 (8.6) | 11.8 (8.0) |
| CRP, mg/L | 16.7 (27.2) | 17.5 (27.6) |
| DAPSA score | 48.7 (22.6) | 49.0 (22.0) |
| % BSA of psoriasis ‡ | 18.3 (18.5) | 28.7 (19.1) |
| PASI total score | 8.5 (8.3) | 12.0 (9.3) |
| Baseline quality of life scores | ||
| DLQI total score | 8.7 (6.9) | 9.8 (7.2) |
| EQ-5D VAS score | 52.5 (21.0) | 51.5 (20.9) |
| SF-36 domain scores | ||
| Bodily pain | 37.9 (19.7) | 38.5 (20.4) |
| General health | 44.6 (19.3) | 44.5 (19.4) |
| Mental health | 64.4 (21.8) | 64.2 (21.6) |
| Physical functioning | 41.8 (26.2) | 42.6 (26.2) |
| Role emotional | 71.7 (27.0) | 72.7 (26.8) |
| Role physical | 43.9 (25.0) | 44.1 (25.4) |
| Social functioning | 63.3 (27.4) | 64.7 (27.7) |
| Vitality | 40.6 (21.8) | 41.7 (21.1) |
| WPAI—activity impairment | 53.0 (25.3) | 50.7 (24.9) |
Data presented are mean (SD) or n (%).
*Placebo: n=134, ixekizumab: n=268.
†Placebo: n=68, ixekizumab: n=156.
‡BSA severity ratings: <3%=mild, 3%–10%=moderate, >10%=severe.
BMI, body mass index; BSA, body surface area; cDMARD, conventional disease-modifying antirheumatic drug; CRP, C reactive protein; DAPSA, Disease Activity Index for Psoriatic Arthritis; DLQI, Dermatology Life Quality Index; EQ-5D, European Quality of Life-Five Dimensions; PASI, Psoriasis Area and Severity Index; SF-36, 36-Item Short-Form Health Survey; TNFi, TNF inhibitor; VAS, Visual Analogue Score; WPAI, Work Productivity and Activity Impairment.